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Emergence Agitation is a frequent complication in the pediatric postoperative population; 
with up to 80% incidence (Stamper, Hawks, Taicher, Bonta & Brandon, 2014). These 
patients will present with crying, overexcitement, thrashing, agitation and is seen within 
the first 30 minutes of emergence of general anesthesia (Mohkamkar, Farhoudie, Alam-
Sahebpour, Mousavi, Khani & Shamomhammadi, 2014). Dexmedetomidine, a selective 
alpha 2 agonist, reduces norepinephrine output, initiates firing of inhibitory neurons such 
as the gama aminobutric acid system and reduces release of substance P and other 
catecholamines. These actions provide the patient with sedation, analgesia, and anesthesia 
(Nagelhout & Elisha, 2018). Due to the mechanism of action of dexmedetomidine, 
bradycardia and hypotension have been seen in pediatric patients. This has put a limit on 
the use of dexmedetomidine in this population. The purpose of this systematic review was 
to examine efficacy and side effects of various doses of dexmedetomidine to prevent 
emergence agitation in the pediatric postoperative patient. A comprehensive literature 
review was completed with the use of CINAHL Plus with full text, PubMed and Google 
Scholar. Preferred Reporting Items for Systematic Meta-Analysis (PRISMA), was used as 
guidelines to assist in proper identification of articles. The quality and critical appraisal of 
each randomized control trial was determined by the Critical Appraisal for Summaries of 
Evidence (CASE) worksheet. A cross study analysis table was created and used to analyze 
results of all studies. The findings of this systematic review determined dexmedetomidine 
was beneficial in emergence agitation prevention. Dexmedetomidine dosed at 0.5 mcg/kg-
1mcg IV boluses and 1 mcg/kg – 2 mcg/kg intranasal sprays provided good relief with 
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Dexmedetomidine Use in the Pediatric Postoperative Patient with Emergence Agitation: 
A Systematic Review  
Background/Statement of the Problem 
 
Emergence agitation, also known as emergence delirium, is a common phenomenon 
in postoperative pediatric patients after receiving anesthesia, specifically sevoflurane or 
desflurane anesthesia (Garg et al., 2018). Emergence agitation can happen in any patient 
at any age but has been found to occur three to eight times more commonly in pediatric 
patients (Stamper et al., 2014).  The incidence of emergence agitation is the highest in 
children who are younger than six years old, have a history of anxiety, specifically 
preoperative anxiety, and experience a fast emergence from general anesthesia (Stamper 
et al., 2014).  Emergence agitation is defined as “a mental disturbance during the 
recovery from general anesthesia consisting of hallucinations, delusions, and confusion 
manifested by moaning, restlessness, involuntary physical activity, and thrashing about in 
bed” (Stamper et al., p. 480). Sevoflurane, an anesthetic commonly used in general 
surgery, is found to have the highest incidence of emergence agitation in pediatrics (Peng 
& Zhang, 2015).  
The child with emergence agitation presents with restlessness, combative 
movements, thrashing, confusion, and may be inconsolable (Zhu, Wang, Zhu, Niu, & 
Wang, 2015). All of these factors may cause discomfort to the patient, parents, post-
operative registered nurses (RNs) and anesthesia providers. Emergence agitation also 
puts the patient at risk for self-injury including wound dehiscence and dangerous removal 
of various medical catheters that may be in place in the post-operative phase (Stamper et 
al., 2014). 
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The etiology of emergence agitation is uncertain; it may be related to pain, 
behavioral issues, anxiety, surgical type, character of patient, and the anesthesia used 
(Kim, Kim, Yoon, & Kil, 2015). One such sedative is dexmedetomidine, which is a 
highly specific alpha 2 agonist that produces a calming effect. It relieves anxiety without 
effecting the respiratory drive, which makes this medicine very beneficial for pediatric 
patients (Garg et al., 2018). The effectiveness of dexmedetomidine may be based on its 
unique pharmacological characteristics. It has been found to be useful in emergence 
agitation in adults as well (Garg et al., 2018). There is lack of labeling on the use of 
dexmedetomidine in pediatrics, but some literature suggests that it may be favorable for 
the pediatric population. 
 According to Mahmoud and Mason (2015), dexmedetomidine is found to be 
advantageous in decreasing emergence agitation in pediatric patients in the perioperative 
phase due to many factors such as neuro-protection, anxiolysis, analgesia, sympatholytic, 
and lack of respiratory depression. The intraoperative administration of dexmedetomidine 
has been shown to reduce emergence agitation in pediatric patients. Not only does it 
provide analgesia and anxiolysis but the use of dexmedetomidine intraoperatively can 
decrease the amount of anesthetics used, which in itself may be a triggering agent for 
emergence agitation. (Kim et al., 2015). According to Qiao, Xie, and Jia (2017), 
dexmedetomidine has beneficial effects preoperatively, intraoperatively, and 
postoperatively in pediatric patients.  
             There seems to be no common protocol for preventative measures or even 
diagnosis of emergence agitation (Stamper et al., 2014). Dexmedetomidine has been 
identified as a useful preventative measure (Kim et al., 2015). Other preventive measures 
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include comfort measures and small doses of fentanyl (Nagelhout & Elisha, 2018).  The 
purpose of this paper was to conduct a systematic review to examine the efficacy and side 
effects of various doses of dexmedetomidine to prevent emergence agitation in the 
pediatric postoperative patient. 






The principal databases used to perform this systematic review included CINAHL 
Plus with full text, PubMed, and Google Scholar. The keywords used included 
emergence agitation, sevoflurane, dexmedetomidine, intraoperative, and pediatrics. The 
time period of the search was limited to ten years.  
Emergence Agitation/Delirium 
 Emergence agitation, also known as emergence delirium and post anesthetic 
excitation, can occur in patients of any age. It was first described in the 1960s in a 
retrospective research study performed on patients who received general anesthesia. This 
study reviewed 14,436 cases and discovered the incidence of emergence agitation was 
highest in childhood, decreased in middle aged patients, and had a slight increase in the 
elderly (Eckenhoff, Kneale & Dripps, 1961). This highest incidence of emergence 
agitation in children remains true to this day. It is a frequent problem in the pediatric post 
anesthetic care unit. The incidence of pediatric emergence agitation can range from 10 to 
80% (Mohkamkar et al., 2014). The large range of pediatric emergence agitation, which 
some studies report from 2% to 80%,  is most likely due to the differing anesthetic 
techniques used on children (Stamper et al., 2014). The large range can also be related to 
the varying scoring systems used to determine emergence agitation (Dahmani et al., 
2010). About four million children undergo general anesthesia each year and emergence 
agitation remains a significant problem (Mohkamkar et al., 2014). 
 Pediatric emergence agitation is a postoperative occurrence associated with 
digressive cognitive and psychomotor ways of acting (Stamper et al., 2014). Examples of 
these characteristics include crying, overexcitement, thrashing, and agitation. Emergence 
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agitation occurs within the first 30 minutes of emergence from general anesthesia, but it 
can last up to two days (Mohkamkar et. al., 2014). Post hospitalization behavioral 
changes (PHBC) are also associated with emergence agitation and 73% of children have 
been found to have these changes which include sleep disturbance, night terrors, 
separation anxiety, and aggression towards providers or caregivers (Pickard, Davies, 
Birnie & Beringer, 2014).  
Emergence agitation is noted to be one of the major causes of frustration among 
parents and medical workers in the postoperative phase (Makkar, Bhatia, Bala, Dwivedi 
& Singh, 2016). These characteristics associated with this syndrome can put the patient, 
family, and medical staff at risk of injury and can interfere with the child’s recovery time. 
The child may be at risk of removing certain medical catheters, dressings, and monitoring 
devices needed in the postoperative period and can cause self-harm (Mohkamkar et. al., 
2014). Adverse effects of emergence agitation may be transient but can defer discharge 
from the post anesthetic care unit due to the risk of self-injury and injury to family or 
caregivers. The extra care required from the nursing team to care for a patient presenting 
with emergence agitation may strain nursing resources and cause dissatisfied post 
anesthetic care (Costi et al., 2014). 
 A key way to manage pediatric emergence agitation is to identify the phenomenon 
quickly (Stamper et al., 2014). Over the years, there has been a paucity of dependable and 
validated scales to measure emergence agitation in pediatrics. The lack of a standardized, 
accepted measurement tool contributes to the wide range of incidence of emergence 
agitation that is reported in the literature (Stamper et al.). Also, the lack of standardized 
measurement tools makes it difficult for providers to find a definite treatment for 
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emergence agitation (Stamper et al.). There remains an absence of prophylactic treatment 
for emergence agitation. (Costi et al., 2014). Treatment for emergence agitation has been 
suggested but no study has found one approach to be superior to the others (Mohkamkar 
et al, 2014). The treatment of emergence agitation is still up for debate based on the value 
of the interventions. (Stamper et al., 2014).  
               To determine emergence delirium in adults, medical providers use the Level of 
Consciousness-Richmond Agitation and Sedation Scale (LOC-RASS), but it has not been 
validated for pediatrics (Stamper et al., 2014). In 2004, the Pediatric Anesthesia 
Emergence Delirium (PAED) scale (Table 1) was developed due to the lack of standard 
of care regarding emergence agitation.  
Table 1 
Pediatric Anesthesia Emergence. Delirium Scale 
 
Mohkamkar, M., Farhoudi, F., Alam-Sahebpour, A., Mousavi, S., Khani, S., & 
Shamomhammadi, S. (2014). Postanesthetic emergence agitation in pediatric patients 
under general anesthesia. Iranian Journal of Pediatrics,24(2), 186. 
 
The PAED scale was created in an attempt to increase knowledge and 
communication to prevent unwanted side effects from emergence agitation (Costi et al., 
2014). The PAED scale is more frequently used in studies after 2004 but its use is 
inconsistent in clinical practice and in research. It was developed based on a theoretical 
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framework of agitation, which focuses on changes in consciousness and cognition; this 
aids in distinguishing  emergence agitation from pain. The PAED scale consists of five 
characteristics that are each scored by using a five-point scale. The five characteristics 
consist of the child’s state of consciousness, ability to focus attention, ability to 
thoughtfully organize external stimuli, psychomotor behavior, and emotional behavior. A 
PAED score higher than or equal to 10 determines the presence of emergence agitation 
(Costi et al., 2014). 
The PAED scale has been reported to be a more reliable and valid measurement 
for pediatric emergence agitation than the LOC-RASS scale (Costi et al., 2014). Stamper 
et al. (2014) performed a quality improvement project to evaluate the identification of 
pediatric emergence agitation by implementing the use of the PAED scale in the pediatric 
PACU. Four hundred patients were assessed using the PAED scale and the LOC-RASS 
scale in two different periods, 200 patients in the retrospective audit and 200 patients in 
the implementation period. A retrospective chart review was completed using LOC-
RASS from perioperative electronic health records one year before the implementation 
period. A one-year time period was chosen to lessen the influence of education needed 
for perioperative staff members. Then data was collected during the implementation of 
the PAED scale using LOC-RASS and PAED scale. The incidence of pediatric 
emergence agitation in the implementation period with the LOC-RASS scale was 7.5% (n 
= 200) and the PAED scale was 11.5% (n = 198), whereas the incidence of emergence 
agitation only occurred in about 3% of the retrospective period population. But there was 
little difference in acknowledging emergence agitation in the implementation period; 
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emergence agitation was assessed in 12 patients with the LOC RASS and the PAED scale 
during the implementation period.  
Effect sizes (ES) were calculated to establish the clinical significance of the 
differences in pediatric emergence agitation of each tool. The incidence between PAED 
scale during the implementation period and LOC-RASS during the retrospective was an 
ES of 0.79 or 95%. This suggests that the PAED scale was more likely to identify 
patients with emergence agitation than the use of LOC-RASS in the retrospective period. 
After analysis of all findings, this study suggested that PAED scale is more sensitive in 
identifying patients with emergence agitation after emergence of general anesthesia. The 
tool allows medical practitioners to better identify patients who are demonstrating a 
decrease level of consciousness, restless behavior, or both. The use of LOC-RASS may 
lead to false negatives (Stamper et al., 2014). 
Emergence Agitation Risk Factors  
Although emergence agitation was discovered in the 1960s, the etiology of 
emergence agitation is still unknown but various factors can be associated with it 
(Makkar et al., 2016). It is important for the anesthesia providers and postoperative 
nursing team to identify the risk factors for emergence agitation to manage them 
appropriately. The risk factors associated with emergence agitation is highest among 
children who are younger than six years of age, have preoperative anxiety, pain, general 
anesthesia,  rapid emergence from general anesthesia, and head and neck surgery 
(Stamper et al., 2014).  
Age. Children who are preschool age, younger than six years old, have been 
associated with emergence agitation more frequently (Stamper et al., 2014). Overall, the 
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pediatric brain is a mirror image of normal age-related regressive processes which cause 
a continuous decline in norepinephrine, acetylcholine, dopamine, and gama-aminobutyric 
acid (GABA). This puts young children at risk of developing emergence agitation 
(Kanaya, 2015). Mokhmakar et al. (2016) stated that children in the age range of 4-6 
years old are most sensitive to emergence agitation based on their inability to cope related 
to rapid awakening in an unknown environment and psychological immaturity. 
Preoperative Anxiety. Children with high anxiety levels at baseline and 
preoperative anxiety upon entering the operating room have been linked to emergence 
agitation (Stamper et al., 2014). Up to 65% of pediatric patients receiving anesthesia for 
surgical procedures will develop extreme fear and anxiety in the pre-operative unit and 
during induction of anesthesia (Kain et al., 2004). It also has been noted that children 
with anxiety during inhalation induction have a higher incidence of emergence agitation 
(Kanaya, 2015). The anxiety can be linked to separation anxiety, fear of anesthesia, 
surgery, the setting, and outcome of procedure (Kain et al.). Also, children with 
emotional, behavioral, and impulsive personality disorders will have a higher incidence 
of emergence agitation (Kanaya, 2015).  
Pain. Inadequate pain relief can cause extreme agitation in children if no 
interventions are provided. Pain can actually mimic the emergence agitation 
phenomenon. It is very important to determine if pain is the cause of agitation or if 
emergence agitation is actually present. This is further complicated by the fact that 
assessing pain in the pediatric patient can be very challenging as is. The PAED scale 
includes a section regarding pain to help determine the presence of emergence agitation 
versus pain (Costi et al., 2014). Although pain can be associated with agitation in 
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children, many studies have found that in procedures not associated with pain, the child 
may still present with emergence agitation, especially if the patient has received 
sevoflurane anesthesia (Kanaya, 2015). For example, in many ophthalmologic cases 
where no postoperative pain is present and the child received sevoflurane, emergence 
agitation presented (Kanaya). Therefore, with lack of pain, emergence agitation still 
presents (Mokmahkar et al., 2014).  
General Anesthesia. Inhalation of anesthetics are used to provide general 
anesthesia. This is considered an “altered physiological state characterized by reversible 
loss of consciousness, analgesia, amnesia, and some degree of muscle relaxation” 
(Butterworth, Mackey, & Wasnick, 2018). The first anesthetics originated in the 1800’s; 
with advanced technology and pharmacokinetics new anesthetics have been derivated 
from the original anesthetics with more ideal properties and side effects. The two most 
commonly used anesthetics include desflurane and sevoflurane. Desflurane is an 
inhalation anesthetic first introduced in 1993 and sevoflurane was introduced in 1995 in 
the United States (Nagelhout & Elisha, 2014). The increased use of sevoflurane and 
desflurane in medically advanced countries are associated with emergence agitation 
(Dahmani et al., 2010)  
 Desflurane is halogenated with fluorine and has a low solubility in blood and 
body tissues. This ensures that a very rapid induction and emergence of anesthesia may 
occur (Butterworth, Mackey, & Wasnick, 2018). Multiple studies suggest that desflurane 
is associated with emergence agitation due to the rapid induction and recovery time 
(Bedaway, 2018). But there is very little data on what drugs to use to prevent emergence 
agitation related to desflurane use (Makkar et al, 2016). Although desflurane has been 
 11 
linked to emergence agitation, sevoflurane has gained more popularity and is used more 
routinely in the pediatric population. 
 Sevoflurane is halogenated with fluorine but has a slightly higher blood solubility. 
One benefit of sevoflurane is the non-pungency, less irritation rapid induction and 
emergence. These factors make it a great choice for smooth and fast induction and 
emergence of pediatric patients (Butterworth, Mackey, & Wasnick, 2018). The child can 
easily breathe this anesthetic in by face mask and works very quickly. It will be given 
continuously during the surgical procedure to keep the child under general anesthesia. It 
is turned off when it is time for the child to wake up. But since sevoflurane’s launch, it 
has been associated with emergence agitation, predominately in pediatric patients (Costi 
et al., 2014). It has been suggested that sevoflurane anesthesia may cause triggering 
events or even a neurotoxic effect in the central nervous system (Costi et al). Sevoflurane 
has an epileptogenicity that may be the triggering cause of emergence agitation. (Kanaya 
et al., 2013). Although rapid awakening from sevoflurane and painful procedures are 
linked to emergence agitation, some studies have found even with a slow awakening from 
sevoflurane anesthesia and nonpainful procedures, pediatric patients present with 
emergence agitation (Na, Song, Hwang, Do, & Oh, 2012).  
 Rapid Emergence. Emergence agitation is precipitated by rapid emergence from 
anesthesia and short acting volatile anesthetics, specifically sevoflurane. Rapid 
emergence may cause a dissociative state, so when children awaken from anesthesia in 
this state they will present with altered cognitive perception (Dahmani, et al., 2010). Kim 
et al. (2015) performed a meta-analysis of randomized controlled trails (RCTs) to 
investigate the incidence and severity of emergence agitation related to the use of 
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desflurane and sevoflurane anesthetics. They reviewed 12 RCTs with a total of 1127 
patients. Five hundred and eighty-eight patients received desflurane anesthesia and 608 
received sevoflurane anesthesia. Eight studies include patients in the age range of one 
year to eight years old, while the four studies include children over the age of ten. 
Overall, they found that sevoflurane and desflurane both had equivalent incidences of 
emergence agitation at 1.21 and with low heterogeneity, even with desflurane having a 
more rapid awakening time than sevoflurane.   
Surgery Type. Otorhinolaryngological, ophthalmological, abdominal, and 
orthopedic surgical procedures have been closely linked to emergence agitation. 
(Mohkamkar et al., 2014). In fact, any surgery involving the head and neck are associated 
with increased risk of developing emergence agitation (Stamper et al, 2018). The specific 
physiological compromise during these surgeries increase the risk (Zhu et al., 2015). 
Otorhinolaryngological and ophthalmological surgeries were discovered to be risk factors 
of emergence agitation in the 1960s. It was described as a “sense of suffocation” while 
the patient awakened from anesthesia; there is no randomized controlled trials to backing 
this hypothesis (Kanaya, 2015).  
A study performed by Mohkamkar et al. (2014) compared the prevalence of 
emergence agitation in 134 children aged three to seven years. Each child underwent an 
elective surgical procedure, either an otorhinolaryngological surgical procedure, 
abdominal surgery, orthopedic surgery, urology surgery, or ophthalmic surgery. Out of 
all five surgeries, otorhinolaryngological surgical procedures had the highest incidence of 
emergence agitation. A significant relationship between the site of operation, specifically 
the head and neck, and occurrence of emergence agitation (P<0.05) was found.  
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Otorhinolaryngological surgeries were linked to higher pain and increased anxiety with 
induction (Mohkamkar et al). 
Prevention of Pediatric Emergence Agitation 
Emergence agitation puts the pediatric patient at risk of harm to self and delay of 
recovery time. It also requires extra care and monitoring from the medical and nursing 
staff and can put them at risk of injury as well. The patient’s family or caregivers may be 
dissatisfied and upset regarding the emergence agitation and blame the symptoms on the 
anesthetic management (Costi et al., 2014).  Preventative measures will be required, 
which include pharmacological, physical restraint, or comfort measures. The most 
frequent preventative measure is pharmacological (Costi et al). The patient cannot be 
discharged until the emergence agitation has subsided and the patient is safe. 
 Pharmacologic Management. Frequently used medications for emergence 
agitation treatment are mainly opioids and sedatives. Some of these drugs may have 
adverse effects on the patient and may delay recovery and discharge time for the patient. 
(Costi et al., 2014). Frequently used drugs to help prevent or stop the incidence of 
emergence agitation include midazolam, ketamine, dexmedetomidine, fentanyl, 
remifentanil, NSAIDs, and propofol boluses (Costi et al.). Each pharmacological 
intervention has different molecular mechanisms that can influence the patients’ 
outcomes. For example, a bolus of fentanyl during induction of anesthesia has been 
shown to reduce the incidence of emergence agitation, but it has negative side effects 
such as respiratory depression and retching (Kanaya, 2015). 
Mohkmakar et al. (2014) performed a cross sectional descriptive and analytic 
study on 747 pediatric patients aged 3-7 who underwent general anesthesia to determine 
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the associated risk factors and prevalence of emergence agitation in pediatric patients 
undergoing general anesthesia. Mohkmakar et al. (2014) found that midazolam, a 
benzodiazepine that provides amnesia and anxiolysis, was used as a premedication for 
some patients in this study and no increased incidence of EA was found with this use of 
this sedative medication. Propofol and ketamine was used intraoperative with the 
anesthetic sevoflurane and there was lack of incidence related to the use of both of these 
as well. 
The choice of the anesthetic can prevent emergence agitation as well. Another 
anesthetic option for children is the use of propofol. Propofol is a 2, 6-diisopropyl phenol. 
It has rapid distribution after intravenous bolus dose to brain and high perfused organs. 
This leads to rapid induction and rapid reawakening after sedative and anesthetic doses 
(Nagelhout & Elisha, 2018). The use of propofol for induction has not been proven to 
reduce emergence agitation, but the use of it after induction has been shown to reduce 
emergence agitation (Kanaya, 2015). A meta-analysis compared the use of sevoflurane in 
560 patients and the use of propofol in 548 patients. This study found that 95% of the 
patients had lower incidence of emergence agitation with the use of propofol (Kanaya et 
al., 2013).  
Dexmedetomidine has been linked to a large reduction in risk of EA (Costi et al., 
2014). In one study it was found to be the most appropriate intervention in preventing 
sevoflurane- related emergence agitation (Kanaya, 2015). Costi et al. (2014) performed a 
systematic review regarding involved 137 studies and 14,045 children. Participants 
included children under the age of 18 years old who were to receive general anesthesia. 
The children were separated into two groups based on alternative general anesthesia 
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versus use of sevoflurane and use of sevoflurane versus sevoflurane with an adjunct. This 
systematic review found that propofol, halothane, dexmedetomidine, opioids, and 
ketamine all reduce the risk of EA. Thirty-four studies compared sevoflurane and 
halothane for risk of emergence agitation; all studies found the use of halothane has a 
lower risk of emergence agitation compared to sevoflurane. Propofol at the end of 
anesthesia was used in five studies; 1mg/kg boluses were administered at the end of 
anesthesia and showed a decrease in emergence agitation. One study used 3 mg/kg bolus 
of propofol for induction and showed no effect on the risk of emergence agitation, along 
with another study who used 2-2.5 mg/kg bolus and found no reduction of emergence 
agitation as well. Ketamine as oral premedication was found to reduce overall risk of 
emergence agitation in two studies, where as one study found no reduction of emergence 
agitation with the use of ketamine after induction of anesthesia. Three other studies did 
find that ketamine as a 0.25mg/kg bolus at the end of anesthesia reduces the risk of 
anesthesia. Twelve studies showed an overall decrease in risk of emergence agitation 
with the use of IV fentanyl. Twelve studies investigating this intervention found a 
significant reduction in the risk of EA (RR 0.37, 95%). Another added four studies found 
that after dexmedetomidine was used there was a lower risk of emergence agitation as 
well (Costi et al.) 
Use of Dexmedetomidine to Prevent Pediatric Emergence Agitation 
Background. Dexmedetomidine, also known as precedex, is part of the imidazole 
class and is an alpha 2 agonist with a short half-life. It is a freely soluble in water with a 
ph of 4.5-7.0 and is preservative free (Nagelhout & Elisha, 2018) and it is administered 
via intravenous infusion.  Alpha 2 receptors are G-protein-coupled receptors, when 
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activated by dexmedetomidine, inhibit calcium channels, activate potassium channels, 
and provide direct modulation of the exocytic release of proteins, which produces 
hyperpolarization of cells and inhibit cells (Nagelhout & Elisha, 2018). 
Dexmedetomidine’s alpha 2 receptor mediated side effects are generated by its effect in 
the locus ceruleus and spinal cord. The main site of action of this medication is at the 
pontine noradrenergic nucleus in the locus ceruleus. Dexmedetomidine provides a 
sedative effect by binding to the alpha 2 receptors in the locus ceruleus, reducing 
norepinephrine output and initiating the firing of inhibitory neurons such as the gama 
aminobutric acid system. Dexmedetomidine also binds to the alpha 2 receptors found in 
the dorsal horn and supra-spinal sites, which reduces the release of substance P and 
reduces the release of other catecholamines (Pickard et al., 2014).  
Dexmedetomidine has sedative, analgesic, and cardiovascular sympatholytic 
actions, is an anxiolytic, and reduces post-operative shivering (Nagelhout & Elisha, 
2018). It is used commonly in anesthesia and intensive care (Bedirli et al., 2017). 
Dexmedetomidine can be used intraoperatively and is known to reduce intravenous and 
inhaled anesthetic use in the operating room. It also can be used outside of the operating 
room to help with anxiety and analgesia. The use of dexmedetomidine is approved for up 
to 24 hours for sedation in a critical care unit, as well as sedation for short term surgical 
procedures (Nagelhout & Elisha, 2018). Dexmedetomdiine has been found useful in the 
pediatric perioperative period to help control emergence agitation. It enhances the 
tolerance, weaning of narcotics and lessens the amount of sedation needed for 
mechanically ventilated patients (Nagelhout & Elisha, 2018).  
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Dexmedetomidine produces a stage 2 non rapid eye movement sleep through 
initiation of the endogenous sleep-promoting pathway. It will induce a conscious 
sedation; the patient can be drowsy yet arousable (Zhu et al., 2015). A unique 
characteristic of dexmedetomidine is that it has little to no respiratory depression. This is 
beneficial because dexmedetomidine will provide analgesia with lack of respiratory 
depression (Pickard et al., 2014). The brain respiratory center is able to remain responsive 
to carbon dioxide levels and airway patency and the airway reflexes are present as well. It 
produces a sedation that is similar to patients’ natural sleep while they remain easily 
arousable. The medication does not change cerebral metabolism but decreases cerebral 
blood flow because of cerebral vasoconstriction. A neuroprotective effect has also been 
noted. The dose of dexmedetomidine can be given via bolus 1 mcg/kg over 1- minute 
followed by an infusion at 0.2-0.7 mcg/kg/hr (Butterworth, Mackey, & Wasnick, 2018). 
 Although dexmedetomidine has unique benefits, it does have some unwanted side 
effects. It may cause bradycardia and decrease blood pressure due to its sympatholytic 
effects. It has been reported to cause sinus arrest after a bolus dose of dexmedetomidine 
in some pediatric patients. It also may cause transient hypertension with rapid initial 
loading doses or high maintenance doses due to vasoconstriction. Dose dependent 
hypotension is considered normal in this drug (Nagelhout & Elisha, 2018).  These 
cardiovascular effects are from the stimulation of CNS alpha receptors and systemic 
vasodilation that ensues. There is a reduction in myocardial oxygen demand which 
provides an antianginal effect (Nagelhout & Elisha). These hemodynamic side effects 
cause providers to limit the use of it in anesthesia pediatric practice (Bedirli et al., 2017).  
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 Prevention of Emergence Agitation. There is a lack of recommendations 
regarding what medications to use to prevent emergence agitation. Some studies suggest 
the use of fentanyl, midazolam, ketamine, NSAIDs, alpha 2 agonists, and/or propofol. As 
discussed above, dexmedetomidine has many pharmacological benefits that other 
pharmacological agents do not, such as a conscious sedation, analgesia, anxiolysis, and it 
also does not cause respiratory depression. The literature related to dexmedetomidine for 
the use of prevention of emergence agitation is abundant. Many RCTs do expose the fact 
the dexmedetomidine can be beneficial, but some studies found side effects of 
dexmedetomidine may outweigh the preventative emergence agitation benefits. 
Kim et al. (2015) conducted a randomized control trail to study the appropriate 
dose of dexmedetomidine, given the reported side effects of prolonged sedation and 
cardiovascular complications associated with administration. Twenty-one children 
participated in the study, all between the ages of 2 and 12 years old, all undergoing either 
a tonsillectomy, adenoidectomy, or both procedures. All patients received general 
anesthesia for the procedure, were maintained with desflurane, and dexmedetomidine was 
given intravenously before the start of surgery. A scale called the Emergence Agitation 
Scale, developed by Cole et al. (2002), was used to detect emergence agitation. Kim et al. 
(2015) chose this scale based on its previous use in identifying emergence agitation with 
the use of dexmedetomidine. A score of greater than 4 or 5 was considered positive for 
emergence agitation. In the event that a patient experienced emergence agitation, a  0.1 
mcg/kg dose of dexmedetomidine greater than the one before would be administered. If 
no emergence agitation was experienced, the dose of dexmedetomidine would be 
decreased by 0.1 mcg/kg. They used the Dixon’s up and down sequential method to 
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determine threshold of amount of increase or decrease of medication administered. If a 
patient had a pain score > 8 or needed rescue medication for emergence agitation they 
would give nalbuphine 0.1 mcg/kg.   
Nine patients developed emergence agitation. They all received nalbuphine 0.1 
mcg/kg, the 50% effective dose (0.25mcg/kg) of dexmedetomidine, and the 95% 
effective dose (0.38mcg/kg) of dexmedetomidine. Cardiovascular symptoms, such as 
bradycardia or hypotension, did not occur in any of the children upon administration of 
dexmedetomidine. This may be due to the fact that intubation and a bolus dose of 0.2 
mg/kg of atropine occurred after the administration of dexmedetomidine, so stimulation 
prevented the cardiovascular complications. Prolonged sedation was not observed with 
participants who received dexmedetomidine. This could be contributed to the fact that the 
doses were smaller compared to other studies (Kim et al., 2015). 
Makkar et al. (2016) performed a study comparing 100 patients who randomly 
received either 0.3 mcg.kg of dexmedetomidine, 1 mg/kg propofol, or 0.9% saline 15 
minutes before the end of surgery. The patients were between the ages two and eight 
years, American Society of Anesthesiologist (ASA) physical status of 1 or 2 and 
scheduled for general anesthesia with a single-shot caudal block for elective infra-
umbilical surgery. No premedication was given to the children, the parents were present 
for induction, and sevoflurane was used for inhalation induction. The PAED scale was 
used and a score of 10 or more was consistent with diagnosis of emergence agitation. 
Emergence agitation was found in 9.4% (n = 32) of children who received 
dexmedetomidine intraoperatively, 13.9% (n = 36) of children who received propofol, 
and 40.6%  (n = 32) of children who received saline. Although dexmedetomidine was 
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found to be most effective in preventing emergence agitation, it was associated with 
longer sedation times and longer extubation times. 
A study performed by Bedirliet et al. (2017) compared the use of 
dexmedetomidine and tramadol. Seventy- Seven patients were enrolled in this study and 
received either dexmedetomidine or tramadol intraoperatively for an adenotonsillectomy 
under sevoflurane anesthesia. Each drug was compared based on its hemodynamic 
stability, postoperative pain management, control of emergence agitation, and post-
operative sedation levels. The authors found that both dexmedetomidine and tramadol 
were effective in reducing emergence agitation. Patients received either 1 mcg/kg IV 
bolus of dexmedetomidine (Group D; n = 38) or 2 mg/kg IV dose of tramadol (Group T; 
n = 39). Tramadol was associated with a lower incidence of nausea and vomiting, and 
extubation times were shorter with the use of a tramadol. Dexmedetomidine had higher 
incidence of intraoperative bradycardia, hypotension, longer stays in PACU, and 
extended sedation times. There was a lack of a placebo group, so the ability to determine  
the effectiveness of both drugs was limited. In conclusion, both tramadol and 
dexmedetomidine were effective in analgesia control and decreased incidence of 
emergence agitation.  
In summary, conflicting results related to the use of dexmedetomidine for 
prevention of emergence agitation exists and side effects of dexmedetomidine in the 
pediatric population exist. The purpose of this review is to conduct a systematic review to 
examine the efficacy and side effects of various doses of dexmedetomidine to prevent 
emergence agitation in the pediatric postoperative patient. 




            The theoretical framework used to guide this study was Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA). Preferred Reporting Items for 
Systematic Meta-Analysis provides an evidence-based checklist with 27 items and a four-
phase flow diagram. The use of a checklist and flow diagram provide an unequivocal and 
complete report of a systematic review (Liberati et al., 2009). This framework helps 
spotlight common topics, results, and relationships of variables found throughout RCTs. 
The 27-item checklist (Table 1) provides recommendations on what should be reported 
regarding the title, abstract, introduction, methods, results, discussions, and findings. 
(Liberati et al). After each section of the checklist, obligatory guidelines are found that 














Table 1  
27 Item Checklist for Preferred Reporting Items for Systematic Reviews and Meta-
analysis 
  
            
          The four-phase flow diagram (Figure 1) is used to report the total number of 
records found and then the articles excluded along with the reasons for the exclusion. The 
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process of trial and selection is shown through this diagram, as well as the eligibility 
criteria (Liberati et al., 2009). The flow diagram provides a graphical representation of 
the entire process including article identification, screening, eligibility, and what studies 
were included in the final study 
 
Figure 1. Four phase flow diagram for preferred reporting items for systematic reviews 
and meta-analysis (Liberati et al., 2009) 
               Overall, PRISMA is very helpful but lacks detail related to the quality 
assessment of a randomized control trial. The Critical Appraisal for Summaries of 
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Evidence (CASE) worksheet was used to critically appraise the included studies (Foster 
& Shurtz, 2013). 









         The purpose of this paper was to conduct a systematic review to examine the 
efficacy and side effects of various doses of dexmedetomidine administration in 
prevention of emergence agitation in the pediatric postoperative population.  
Outcomes  
            Outcomes included incidence of emergence agitation and side effects in the 
postoperative phase in pediatric patients.  
Inclusion/Exclusion Criteria 
          Inclusion criteria included studies specific to emergence agitation in the pediatric 
population; subjects less than eight years old; ASA one or two; the use of an emergence 
agitation scale; use of sevoflurane; and the use of only dexmedetomidine for sedation. 
Only randomized control trials or systematic reviews from 2009 to 2018 and in English 
were utilized.  
            Exclusion criteria included any studies before 2009; studies that examine adult 
subjects; studies that do not use an emergence agitation assessment tool; studies that use 
alternative drugs as a placebo; and those not meeting the inclusion criteria. 
Search Strategy 
         Research articles were found via CINAHL Plus with full text, PubMed, and Google 
Scholar. A detailed search was conducted using the search terms dexmedetomidine, 
sevoflurane, pediatrics, emergence agitation, and intraoperative. The PRISMA flowchart 
was utilized to document the process used to select studies for the systematic review. 
Data Collection 
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A separate table was formed to summarize selected outcomes of the individual 
studies (Table 2). 
Table 2 
Data Collection Table: Outcomes of the Study 
 
 
           A data collection table was created to summarize each study, including the design, 
sample, surgical procedure, and method. (Table 3).  
Table 3 




The Critical Appraisal for Summaries of Evidence (CASE) worksheet was used 
for quality assessment of the evidence provided. The quality of the data gathered from the 
studies was determined via the Critical Appraisal for Summaries of Evidence (CASE) 
worksheet (Table 4).  This tool is used to evaluate quality of evidence and provides a 
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standard for evidence-based medicine point of care summaries. It has 10 questions that 
explore the specificity, authorship, reviewers, methods, grading, clarity, citations, 
currency, bias, and relevancy for each study (Foster & Shurtz, 2013). The answers must 
be either “yes”, “no”, or “not completely”.  Each study was reviewed, and the ten 












Data Synthesis & Cross Study Analysis 
The cross-study analysis tool (Table 5) was designed to collect and organize 
information from each study. Each column presents a topic to allow for descriptive 
information to be placed. This table was used to compare each study based on their 
outcomes. 
Table 5 
 Cross Study Analysis Tool 
 
 




















Figure 2 on the next page provides a visual analysis of the search strategy used to 
perform this systematic review. The initial search began with “dexmedetomidine” and 
“pediatrics”. This search yielded 203 results among selected databases. The search term 
“sevoflurane” was added and generated 26 results. Lastly “emergence agitation” was 
added to search term and the years were adjusted to 2009-2018; this yielded 17 results. 
After the article search was performed, 12 studies were excluded for not meeting the 
inclusion criteria listed above. Lastly, the remaining five studies were appraised and 




Figure 2. Completed PRISMA flow diagram demonstrating article identification, 






 Each of the five studies included in this systematic review were reviewed 
individually in this section and illustrated in Appendix A and Appendix B.  Appendix A 
(Tables A1-A6) presents each studie’s demographics and methods used. The main 
information in these study tables include purpose, design, sample, surgical procedure, and 
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method used. Next, Appendix B (Tables B1-B6) presents study outcomes. The main 
information found in these study tables include dexmedetomidine dose, efficacy, adverse 
side effects, and limitations. Appendix C presents Critical Appraisal for Summaries of 
Evidence (CASE) worksheet. This will aid in assessing for reliability, validity, and 
applicability of each study in this systematic review. Appendix D presents the cross-study 
analysis tool. Each study is numbered and examined based on emergence agitation 
incidence, ASA classification/Patient characteristics, anesthetic used, bradycardia events, 
hypotension events, and length of hospital stay.  
Individual Studies 
 A prospective double-blind randomized study performed by Kim et al. (2014) 
(Appendix A, Table A1) assessed the effects of dexmedetomidine infusions with 
sevoflurane requirements, recovery profiles, and emergence agitation in children 
undergoing ambulatory surgery. The surgical procedure consisted of either a hernioplasty 
or orchiopexy. A total of 40 children with ASA 1 between the ages 1-5 years old were 
included in this study. Children with mental retardation, developmental delay, 
neurological or psychiatric illnesses that may be associated with agitation, coagulation 
disorder, spinal anomalies or bilateral procedures were excluded. The patients were 
selected at random into two groups, Group D and Group S. The parents of the patients 
selected remained with the children in the operating room until the child lost 
consciousness to decrease preoperative anxiety. Inhalation induction was performed on 
each child and an intravenous line was placed. After placement of intravenous line, 
Group D received dexmedetomidine and Group S received saline; both received 1 
mcg/kg IV bolus over 10 minutes followed by a 0.1 mcg/kg/hr maintenance infusion until 
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the end of surgery. Each child also received a caudal block to help with postoperative 
pain. ET sevoflurane, mean arterial pressure and heart rate were recorded prior to the 
administration of dexmedetomidine or saline, just after loading doses, ten minutes after 
loading dose, start of operation and every ten minutes until operation was done. 
           The patients were then brought to post anesthetic care unit and EA was assessed at 
arrival and every 5 minutes for up to 30 minutes in PACU. Emergence Agitation was 
assessed with a four-point scale created by Watcha (Kim et al., 2015). Points were given 
based on 0= asleep, 1 = calm, 2= crying but can be consoled, 3- crying and unconsolable, 
4 = agitated and thrashing. Children with a score of 3 or 4 were determined to have 
emergence agitation. Pain and sedation were assessed only with first oral intake, 
discharge time, and adverse effects.  
Outcomes for this study by Kim et al. (Appendix B, Table B-1) found that 
intraoperative dexmedetomidine bolus dose and infusion reduced both anesthetic 
requirements and emergence agitation without delaying discharge in pediatric ambulatory 
surgery.  Emergence agitation was noted to be lower in group D than group S (5% vs 
55%, p=0.001). Mean arterial pressure and heart rated were decreased by 22-28% and 18-
21% in group D compared to group S. Six patients received atropine for bradycardia with 
or without hypotension with the dexmedetomidine bolus dose (P=0.020). The discharge 
time did not differ between either group (Group D, 201 minutes vs Group S, 207 
minutes). There were no adverse effects such as nausea, vomiting, and urinary retention.  
 Evaluation of the integrity of this study by Kim et al., applied from the CASE 
worksheet (Appendix C, Table C-1), suggested that this trial brings an individualized 
topic specific to practice. It also found that there wqas transparency related to the authors, 
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methods, and observers. The study was approved by IRB and informed consent was done 
with each parent. Appropriate exclusion criteria were present. Groups were randomly 
assigned by a computer generated system, but they did not name the system. This study 
did present with some limitations. First, the authors suggested that uncertainty existed 
related to the proper scoring tool for use with EA. Kim et al. (2014) chose the Watcha et 
al. EA scale because it included a consolability component. They had concerns that the 
approved PAED scale did not apply to children who are asleep in PACU. Second, the 
researchers did not assess pain, which has been suggested to interfere with diagnosis of 
EA. Each patient did receive a caudal block, so Kim et al. believed pain was not a factor 
in this scenario. Last, the sample size calculation for each groups’ dexmedetomidine dose 
was based on ET-sevo. ET–sevo, also known as end tidal sevoflurane concentration, tells 
the anesthesia provider how much MAC of sevoflurane the patient has. Based on other 
studies, Kim et al. (2014), monitored the ET-sevo, to help determine effects of 
dexmedetomidine. This suggested that the sample size of 40 patients may have been too 
small. 
 The randomized double-blind study by Di et al. (2017) (Appendix A Table A-2) 
evaluated the use of dexmedetomidine with low concentration sevoflurane vs high 
concentration sevoflurane and its effect on smooth deep extubation, emergence 
characteristics, recovery time, and incidence of airway complications. A total of seventy-
five patients, who were either an ASA I or II, and between the ages 3-7 years old, who 
underwent an adenotonsillectomy were randomly divided into three groups by a 
computer-generated table of numbers. Group D0 consisted of 25 patients who received 
intravenous saline 4mcg/ml IV bolus. Group D1 consisted of 25 patients who received 
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dexmedetomidine 1 mcg/kg IV bolus over 10 minutes. Group D2 consisted of 25 patients 
who received dexmedetomidine 2 mcg/kg IV bolus over 10 minutes. Each group was 
maintained on sevoflurane for at least 10 minutes before deep extubation.  Following 
extubation each patient was placed in a lateral position after adequate spontaneous 
ventilation and a patent airway was determined. Patient was then transferred to the 
PACU. The PAED scale was used to diagnose EA in the PACU. Emergence Agitation 
was defined with a score greater than 10.  
 Outcomes of this study by Di et al (2017) (Appendix B, Table B-2), demonstrated 
that the overall occurrence of emergence agitation was lower with the use of 
dexmedetomidine. After extubation no breath holding, laryngospasm, bronchospasm, and 
hypoxemia were observed. In the PACU, Group D0 (24%) presented with emergence 
agitation and were treated with fentanyl. In Group D1(0%) and Group D2 (0%), 
incidence of emergence agitation was significantly less than Group D0 (p=0.05). The 
times of discharge from PACU to home were longer in group D0 (33.7) and Group D2 
(32.8) compared to Group D1 (25.5). No respiratory complications or nausea/vomiting 
were noted in the PACU in all groups.  
 When evaluating the integrity of this study utilizing CASE questionnaire 
(Appendix C, Table C-2), it was noted that the trial presented an individualized topic 
specific to practice, transparency related to the authors, methods, reviewers and editors. 
Each parent was presented with information and informed consent was obtained. Patients 
were randomly assigned into groups with a computer generated table of random numbers. 
A research observer was assigned to each patient to evaluate the quality of extubation and 
respiratory status. The observer was blinded to drug and groups. The results of this study 
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can be applicable to pediatric population undergoing ENT surgery. This study did have 
some limitations. The first limitation mentioned by the authors was the lack of plasma 
drug levels of dexmedetomidine. Therefore, there was no link between sedation and 
hemodynamic changes of dexmedetomidine in blood. Second, each patient was deep 
extubated, based on the absence of airway responsiveness and continuation of regular and 
spontaneous respiration after laryngopharyngeal suction. Per the Di et al (2017) a benefit 
of deep extubation is improved recovery and increase overall comfort. However, the 
authors did not take this into consideration when determining emergence agitation, so it is 
unclear if this benefitted emergence agitation or make it worse.  
The double-blind randomized control trial by Chen, Wang, Huang, and Fu (2018) 
(Appendix A, Table A-3) evaluated the efficacy of different doses of DEX as a rapid 
bolus to aid in the prevention and treatment of EA in pediatric population. One hundred 
children ranked as ASA I or II, between the ages of 3-7 years old were randomly enrolled 
into five groups (Random number method was used). The control group was group D1 
which received saline IV bolus, group D2 received 0.25 mcg/kg dexmedetomidine IV 
bolus, group D3 received 0.50 mcg/kg of dexmedetomidine IV bolus, group D4 received 
0.75 mcg/kg of dexmedetomidine IV bolus and group D 5 received 1 mcg/kg of 
dexmedetomidine IV bolus. Inclusion criteria was normal intelligence, liver, and kidney 
function, scheduled for elective inguinal hernia repair surgery, no allergies to anesthesia, 
and entered the operating room without parents. The patients were brought into the 
operating room, inhalation induction with sevoflurane was performed and LMAs were 
placed once anesthetized. Once stable vital signs were achieved patients received 
medications based on what group assignment to. Heart rate, mean blood pressure, and 
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oxygen saturation were recorded before study drug was administered and every 5 minutes 
after. When surgery was complete, patients were extubated, and each patient was brought 
to the PACU. Emergence agitation, pain, and adverse effects were assessed in PACU. 
The PAED scale was used to assess emergence agitation, a score > 12 was a diagnosis of 
EA. Propofol 1 mg/kg was given for treatment of EA, if the patient was considered free 
of pain and if the parents or caregiver could not console the patient.  
Outcomes of this study by Chen et al. (2018) (Appendix B, Table B-3), 
demonstrated that the incidence of EA was extremely lower in groups D4 (0%, P < 
0.001) and D5 (0%, P < 0.001), and fewer incidences of EA was observed in group D2 
(5%, P= 0.096) and D3 (5%, P = 0.096). Emergence agitation was found most commonly 
in group D1 (30%). It was noted as the dose of dexmedetomidine increased, the recovery 
time increased, but it was not considered a large difference in total adverse events. There 
were no large differences in adverse events and bradycardia in all the groups. 
Bradycardia was defined as a heart rate decrease by greater than 30% of baseline. Eight 
patients had a 30% decrease in heart rate from baseline but did not require treatment. No 
patient needed treatment for pain, cough, headache, or vomiting. All patients were able to 
breathe spontaneously and maintain their oxygen saturation greater than 98%.  
When evaluating the integrity of this study by utilizing the CASE questionnaire 
(Appendix C, Table C-3), it suggested that the study presented a focused and clear issue. 
Informed consent was done with each patient’s parent and the children were randomly 
assigned into groups using the random number method. Patients were excluded if they 
had an allergy to dexmedetomidine, G-6-PD deficiency, a history of arrhythmia, 
bronchial and cardiovascular disease, abnormal liver function, or a history of use of alpha 
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2 receptor agonist or antagonist. No patient received premedication. A BIS monitor was 
used to determine adequate anesthesia and then dexmedetomidine doses were 
administered at a rate of less than 5 seconds. The results of this study can be applicable to 
the pediatric population receiving inguinal hernia repairs. There were some limitations to 
this study. First, the study used the PAED scale; the authors noted that the subjective 
aspects of this scale may yield differing subjective evaluations by users, though this scale 
has been widely used for the use of emergence agitation. Second, the authors failed to 
mention if the study staff were blinded to the study drugs or if any personally received 
education on the PAED scale. Third, the rate of dexmedetomidine bolus was less than 
five seconds; various studies suggested bolus doses be administered over 10 minutes due 
to hemodynamic issues. It is unclear if the five second bolus skewed the adverse events 
results. Lastly, the sample size was 100 patients from one hospital which rather small and 
involving just one hospital. These findings suggest that the grading system was not 
completely transparent and translatable and that the summary was not completely 
unbiased.  
The randomized double-blind clinical trial by He et al. (2013) evaluated the 
effects of two different doses of dexmedetomidine infusion on the end tidal concentration 
of sevoflurane required for smooth LMA removal and on postoperative recovery 
measures such as emergence agitation in pediatric patients. This trial studied eighty-seven 
patients with ASA scores of I or II, between the ages of 3-7 years old, who underwent 
elective minor surface surgery for less than an hour under general anesthesia. The 
patients were randomly assigned to one of three groups. Group C received saline. Group 
D1 received dexmedetomidine 0.5 mcg/kg and group D2 received dexmedetomidine 1 
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mcg/kg. Each study drug was labeled as study drugs and were prepared by an anesthesia 
nurse independent of the study. Patients were brought into the O.R., connected to 
appropriate monitoring and preoxygenation and inhalation induction with 8% sevoflurane 
was started. Once patient was anesthetized, LMA was placed. The study drug was placed 
on an infusion pump and administered as an IV bolus after LMA insertion. After surgery 
was complete, LMA removal occurred when the sevoflurane concentration reached 2.2%. 
Patients were then transferred to the PACU and kept in the unit until they met an 
Aldrete score of 9 or more and were free from nausea and vomiting. The Aldrete score 
evaluates a patient’s activity, respirations, circulation, consciousness, and oxygen 
saturation. The anesthetist would monitor respiratory complications and emergence 
agitation until arrival in PACU. The emergence time and recovery time were recorded in 
PACU. Behavior in PACU was recorded by a blinded observer with a 5 point scale; 1 for 
sleeping, 2 for awake and calm, 3 for irritable and crying, 4 for inconsolable crying, 5 for 
severe restlessness, disorientation and thrashing around. Scores greater than 3 indicated 
agitation and the patient received propofol 1 mg/kg if unconsolable. If pain was noted by 
complaints or if patient was trying to remove the surgical dressing they received 1 
mcg/kg IV.  
Outcomes of this study by He et al. (2013) demonstrated that emergence agitation 
was lowered with the use of dexmedetomidine. The incidence of emergence agitation was 
significantly lower in group D1 (17%) and in group D2 (6%) compared to group C (42%, 
P=0.003). But groups D1 and D 2 were comparable (P=0.179). Pain was found to be 
similar within all three groups (P=0.719). Hemodynamic issues were noted with a higher 
dose of dexmedetomidine (1 mcg/kg, Group D2). The issues did not overstep 20% of the 
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values prior to dexmedetomidine infusion. No patients suffered from severe respiratory 
complications such as laryngospasm, bronchospasm, or hypoxemia. Breath holding was 
found to be lower in group D2 (3%) than in Group C (27%, P=0.009) but comparable 
between groups D1 and C (P=0.385). Severe coughing was lowest in Group D1 (14%) 
and D2 (6%) as compared to Group C (39%, P=0.005). Groups D1 and D2 were 
comparable (P=0.323). Emergence times were prolonged in group D2 and Group C 
compared to Group D1 (P=0.014). Lastly, the recovery time was prolonged in Group D2 
and Group C compared to Group D1 (P=0.010). 
When evaluating the integrity of this study with the CASE questionnaire 
(Appendix C, Table C-4), it suggested the study addressed a clear and focused issue 
specific to practice and transparency related to the authors and observers. The study was 
approved by an ethics committee and each child’s parents received informed consent. 
The study used a computer generated numbers system to assign groups. This study was 
not completely transparent regarding the research methods transparency and the grading 
system transparency. Some limitations were presented in the study. First, all of the 
procedures in the study were less than an hour and each patient received either a regional 
or local anesthetic block and no opioids were given. If the patient did not receive a type 
of block, or if the procedure was long, the outcomes might have been different. Second, 
each patient was accepted into the study if they were going to receive minor surface 
surgery, but the authors did not elaborate on what specific surgeries were examined. This 
may provide some bias. Third, patients that received 2 mcg/kg of dexmedetomidine in the 
pilot study were noted to be unarousable and sleepy for a long time after surgery, so the 
authors lowered doses in the study. Last, the researchers used an infusion pump to 
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administer the dexmedetomidine per the hospital protocol. The period of infusion was 10 
minutes and it was unsure if this provided an advantage or not.  
The randomized single blinded control study conducted by Lin et al. (2016) 
(Appendix A, Table A-5) evaluated the hypothesis that a single premedication dose of 
dexmedetomidine could reduce preoperative anxiety and also minimize emergence 
agitation in children undergoing cataract surgery, specifically with sevoflurane 
anesthesia. Ninety children from the ages 1 to 8 years old, ASA I or II undergoing 
cataract surgeries were enrolled in this study. Patients were randomly selected into 3 
groups using a computer generated randomization program. Patients in group C received 
intranasal saline, Group D1 received 1 mcg/kg of dexmedetomidine, and Group D2 
received 2 mcg/kg of dexmedetomidine. A masked research assistant administered 
intranasal study drugs 45 minutes before induction of anesthesia and the patient laid 
supine for 2 minutes to help with intranasal dexmedetomidine absorption. Anesthesia was 
induced via inhalational induction and an LMA was placed. All patients received topical 
proparacaine eye drops. After the procedure ended LMA was removed and patient was 
transferred to PACU.  
On arrival to PACU, the patients were monitored for heart rate, blood pressure, 
and oxygen saturations by the PACU nurses. Every 5 minutes the patients were assessed 
with the PAED scale and the CHEOPS scale. PAED scores > 10 were considered 
emergence agitation. If the PAED score was above 15 the patients were treated with 1 
mg/kg of propofol intravenously.  
Outcomes of the study by Lin et al. (2016) (Appendix B, Table B-5) suggest that 
intranasal dexmedetomidine reduced the incidence of postoperative emergence agitation 
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with no delay in emergence time or lack of adverse event. Intranasal dexmedetomidine 
greatly reduced emergence agitation in group D 1 23.3% (P<0.001) and group D2 10% 
(P<0.001). Emergence agitation was found most commonly in group C 80%. This 
suggests a high amount of emergence agitation with just sevoflurane anesthesia. The 
emergence time and PACU stay time were comparable among all three groups. Clinically 
significant bradycardia, were not observed in any of the patients after the 
dexmedetomidine administration. The reductions in heart rate and blood pressure were 
found to not be statistically different in Group D1 and Group D2 (P >0.05).  
When evaluating the integrity of this study utilizing the CASE questionnaire 
(Appendix C, Table C-5) it suggested the study addressed a clear and focused issue. 
There was no transparency related to authorship, design, or methods. Set protocols were 
used for intranasal dexmedetomidine administration, inhalation and maintenance of 
anesthesia, and PACU stay. The authors expressed there was a masked research assistant 
who administered the intranasal dexmedetomidine, but failed to say if anesthesia 
providers or PACU nurses knew which patients received study drugs. The authors failed 
to mention if informed consent was obtained from parents of the patients. Some other 
limitations the authors presented included the fact that the influence of resistance of mask 
inhalation induction may influence emergence agitation. Finally, the authors failed to find 
dose dependent effects of dexmedetomidine related to hemodynamic changes. This 
suggests that intranasal routes may affect the bioavailability of dexmedetomidine and 





 The cross-study analysis table (Appendix D) illustrates each study by number, the 
percentage of emergence agitation found in each study, the characteristics of each patient 
population, the type of anesthetic used, and adverse outcomes including; bradycardia, 
hypotension, and length of hospital stay. All five studies included patients between the 
ages 1-8 years old and ASA I or II. Surgeries varied throughout the studies, including 
hernioplasty/orchiopexy (Kim et al., study 1), adentonsillectomy (Di et al., study 2), 
inguinal hernia repair (Chen et al., study 3), minor surface surgeries (He et al., study 4), 
and cataract surgery (Li et al., study 5). All studies used sevoflurane anesthesia but some 
studies included regional anesthesia as well. Study 1 used sevoflurane but also included a 
caudal block to disregard postoperative pain and focus on results of emergence agitation. 
Study 3 used sevoflurane and ilioinguinal/iliohypogastric nerve blocks in an attempt to 
disregard postoperative pain as well. The studies 2 and 4 used sevoflurane anesthesia 
with no regional anesthesia. Study 5 used sevoflurane but the authors stated they gave 
0.5% proparacaine hydrochloride drops to help with pain postoperatively.  
 All studies compared various doses of dexmedetomidine to a placebo of saline. 
Emergence agitation was assessed in the PACU in all studies. The scale to assess 
emergence agitation varied throughout the studies. The PAED was used in study 2, 3, and 
5. Study 1 used the Watcha EA scale and Study 4 did not state the scale used.  
Overall, the incidence of emergence agitation was decreased with the use of 
dexmedetomidine compared to saline. But based on dexmedetomidine dosing, the 
presence of emergence agitation varied. In study 1 (Kim et al., 2017), group D received a 
1 mcg/kg bolus of dexmedetomidine followed by an infusion of dexmedetomidine of 0.1 
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mcg/kg/hr until end of surgery. Only had 5% of emergence agitation was found in Group 
D compared to group S with 55% emergence agitation. Group S received saline.  In study 
2 (Di et al., 2017), Group D1 received 1 mcg/kg bolus and Group D2 received 2 mcg/kg 
bolus; both had 0% of emergence agitation. Group D0 received saline which presented 
with 6% incidence of emergence agitation.  
In study 3 (Chen et al., 2018), group D1 received saline and presented with the 
most emergence agitation.  Group D 2 received 0.25 mcg/kg bolus of dexmedetomidine 
and 5% of patients presented with emergence agitation. Group D3 received 0.5 mcg/kg 
IV bolus of dexmedetomidine and 5% presented  with emergence agitation. Group D4 
received 0.75 mcg/kg IV bolus of dexmedetomidine and no emergence agitation was 
experienced. Group D5 received 1 mcg/kg IV bolus of dexmedetomidine and just like 
Group D4 0% of emergence agitation was noted. These findings demonstrate that the 
groups D4-D5, with doses of dexmedetomidine 0.75mcg/kg-1mcg/kg boluses, were most 
effective.  
In study 4 (He et al., 2013), group D1 received 0.5 mcg/kg IV bolus of 
dexmedetomidine and 17% presented with emergence agitation. Group D2 received 1 
mcg/kg IV bolus of dexmedetomidine and 6% experienced emergence agitation. Group C 
received saline and there were 42% emergence agitation cases. These findings suggest 
the dosing of dexmedetomidine of 1 mcg/kg IV bolus worked the best. 
 In study 5 (Lin et al., 2016), group C was given saline and had an 80% 
occurrence of emergence agitation. In group D1, which received 1 mcg/kg intranasal 
dexmedetomidine, 23.3% presented with emergence agitation. Group D2 received 2 
mcg/kg of intranasal dexmedetomidine and had a 10% occurrence of emergence 
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agitation. These findings suggest that intranasal doses and bioavailability may work 
better with higher doses, like group D2, 2 mcg/kg intranasal.  
Adverse effects such as hypotension and bradycardia were noted throughout all 
five studies. Studies 2 (Di et al., 2017), 3 (Chen et al., 2018), 4 (He et al., 2013), and 5 
(Lin et al., 2016) did report hypotension and bradycardia all fell within a 20% decrease of 
patients’ baseline. No patient had to be treated in these studies. In study 1, six patients 
were noted to have bradycardia with hypotension and without, all of whom received 
atropine.  
All studies included same day surgeries and no patients had an extended stay due 
to dexmedetomidine. Study 1 (Kim et al., 2017), 3 (Chen et al., 2018), and 5 (Lin et al., 
2016) did not note any delays in recovery time. Study 2, group D0 and group D2, had the 
longest recovery time in PACU. The authors believed this was due to the higher doses of 
dexmedetomidine in group D2 and the use of additional fentanyl for treatment of 
emergence agitation in group D0. Study 4 Group D 2 and group C presented with the 
longest recovery time in PACU. Group D2 received the highest dose of dexmedetomidine 
but group C received saline. Group C was noted to wake up in pain and patients more 
commonly received fentanyl, but all went home on the same day.  






Summary and Conclusions 
Pediatric emergence agitation is a postoperative complication with cognitive and 
psychomotor affects (Stamper et al., 2014). The untoward effects of emergence agitation 
include crying, overexcitement, thrashing, and agitation (Mohkamkar et al., 2014). The 
pediatric patient with emergence agitation is at risk of causing self-harm and harm to 
medical staff and family or caregiver. The patient is also at risk of removal of medical 
catheters, dressings, and monitoring devices that may be needed postoperatively 
(Mohkamkar et al. 2014)). A pivotal way to manage pediatric emergence agitation is to 
diagnose it quickly (Stamper et al., 2014).  
Dexmedetomidine, an alpha 2 agonist, binds to alpha 2 receptors in the locus 
ceruleus, decreases norepinephrine output, and produces analgesia. It also has an 
analgesic action by binding to alpha 2 receptors in dorsal spine and super-spinal sites and 
decreasing the release of substance P (Pickard et al., 2014). Dexmedetomidine also has an 
anxiolytic and reduces post-operative shivering (Nagelhout & Elisha, 2018). Benefits of 
dexmedetomidine include conscious sedation, similar to endogenous sleep patterns, and 
little to no respiratory depression (Zhu et al., 2015). Dexmedetomidine has been linked to 
a large reduction in pediatric emergence agitation. Although it has unique benefits, it 
does come with unwanted side effects. It produces sympatholytic effects that may cause 
bradycardia, and hypotension. It also may cause transient hypertension with rapid initial 
loading doses or high maintenance doses due to vasoconstriction.  
The purpose of this systematic review was to examine the efficacy and side 
effects of various doses of dexmedetomidine to prevent emergence agitation in the 
pediatric postoperative patient. A comprehensive literature review was performed with 
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the use of CINHAL Plus with full text, Pub med, and Google Scholar. Keywords used to 
perform the search included emergence agitation, sevoflurane, dexmedetomidine, 
intraoperative, and pediatrics. The preferred reporting items for systematic reviews and 
meta-analyses was used as the theoretical framework and the PRISMA flow diagram was 
used to aid in the identification of eligible studies based on inclusion and exclusion 
criteria. (Liberati et al, 2009) 
A total of five studies met the inclusion criteria. Data tables were created to 
illustrate key design components of each study. Then, a table was created to illustrate 
outcomes for each study, focusing on dose and efficacy of dexmedetomidine and 
incidence of emergence agitation. The Critical Appraisal for Summaries of Evidence 
(CASE) worksheet was used to perform a critical appraisal of each study. Last, study 
analysis was performed on each individual study that met inclusion criteria. A table was 
created to compare emergence agitation incidence, patient characteristics, anesthetic 
used, dexmedetomidine dose, hypotension/bradycardia event, and length of stay across 
the five studies.  
The findings of this systematic review suggest that overall, the use of 
dexmedetomidine decreases the incidence of emergence agitation in the pediatric 
population. The dose of dexmedetomidine does provide more coverage and efficacy with 
rare adverse side effects. The range of bolus doses was from 0.25 mcg/kg to 2 mcg/kg 
boluses. In the Kim et al. (2014) study, the researchers started a dexmedetomidine 
infusion after the bolus dose. Lin et al. (2016) chose to use the intranasal route instead of 
intravenous. Kim et al. (2014) found the dose of 1 mcg/kg IV bolus followed by a 0.1 
mcg/kg/min dexmedetomidine infusion reduced the incidence of emergence agitation 
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without delaying discharge. Chen et al. (2018) found that 0.75 mcg/kg and 1 mcg/kg IV 
bolus dose prevented emergence agitation with transient decrease in heart rate and blood 
pressure, but was well tolerated in the pediatric population. He et al. (2018) found the 
doses of 0.5 mcg/kg and 1 mcg/kg IV boluses of dexmedetomidine provided the best 
relief of emergence agitation with few side effects. Di et al. (2017) administered doses of 
1 mcg/kg to reduce emergence agitation with no side effects. This study also found the 
efficacy of 2 mcg/kg IV bolus to be useful in emergence agitation reduction, but the 
patients presented with prolonged postoperative recovery. Lin et al. (2016) documented 
the best efficacy of intranasal doses 1 mcg/kg and 2 mcg/kg of dexmedetomidine in 
reduction of emergence agitation with only slight decreases in heart rate and blood 
pressure.  
Overall, the studies revealed that bradycardia and/or hypotension can occur but 
most were within 20-30% of baseline vitals, which was determined to be tolerable in the 
pediatric population. The mean length of recovery was noted to be longest in the groups 
with the highest dose of dexmedetomidine compared to lower doses or groups who 
received saline.  
Several limitations were found in this systematic review. First there were only 
five studies that fit into the inclusion criteria with a limited number of selectivity. Second, 
pediatrics is a specialty population but not all studies were performed in a specialized 
children’s hospital. Both of these limitations could affect the generalizability. There were 
also several limitation throughout the studies in this review. All of the studies used 
sevoflurane for a volatile anesthetic. Two studies, Kim et al. (2014) and Chen et al. 
(2018), used nerve blocks and the study by Lin et al.(2016) used proparacaine eye drops. 
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Di et al. (2017) and He et al. (2013) used only sevoflurane and not other anesthetics. The 
use of these blocks suggests a limitation on the use of dexmedetomidine, potentially 
affecting this study results. Lack of blinding was found in some studies. Three studies 
included in this systematic review were double blinded (Chen et al., 2018; He et al., 
2013; Kim et al., 2013), one was single blinded (Lin, 2016), and the last study was not 
blinded (Di, 2017).  For induction of anesthesia, all studies used inhalation mask 
induction, but only one study listed it as a limitation. The resistance and anxiety of mask 
induction can increase emergence agitation.  
Another limitation noted was the length of time of surgeries; in one particular 
study, He et al. (2013), all surgeries were less than one hour. All studies diagnosed 
emergence agitation, but not all used the same scale. The PAED is the standard tool for 
diagnosis of emergence agitation in pediatrics, but some studies did not use this measure. 
Only three studies, Di et al, (2014), Chen et al. (2018), and Lin et al. (2016), used the 
PAED scale, which suggests a lack of standardized care. Last, four out of five studies 
used intravenous dexmedetomidine and one study, Lin et al. (2016), used intranasal 
dexmedetomidine. This presented a limitation due to the lack of knowledge of dose 
dependent sides effects and the precise bioavailability of the intranasal route.  
In conclusion, this systematic review found that dexmedetomidine was beneficial 
in emergence agitation prevention. Specific doses of dexmedetomidine provided better 
relief of emergence agitation: 0.5 mcg/kg – 1 mcg/kg IV boluses and 1 mcg/kg – 2 
mcg/kg intranasal sprays provided the best relieve with limited adverse effects.  
Next, the recommendations and implications for advanced nursing practice will 
be presented.  
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Recommendations and Implications for Advanced Nursing Practice 
 
When pediatric patients undergo general anesthesia, it is a stressful time for the 
patient, parents, and even the provider. Upon awakening from general anesthesia, the 
pediatric patient can present with emergence agitation, which is yet another stressful 
situation for the patient and those directly involved in care. Emergence agitation can be 
found in up to 80% of pediatric patients (Makkar et al., 2015).   In fact, emergence 
agitation is one of the most significant causes of dissatisfaction in parents and healthcare 
providers and can even result in physical harm to the child (Makkar et al.). The patient 
can present with restlessness, inconsolability, disorientation, delusion, hallucination, self-
injurious behaviors, and memory impairment (Ali & Abdellatif, 2013). Upon transfer to 
PACU, the pediatric patient should be comfortable and resemble what they are like in a 
natural sleep due to dexmedetomidine. The patients', parents’, and medical teams’ 
satisfaction are noted to be higher with the use of dexmedetomidine to prevent emergence 
agitation. The CRNA must be able to recognize the importance of this. This systematic 
review was able to provide a guide for CRNAs on how to make educated decisions 
regarding the use, dose, and efficacy of dexmedetomidine in the pediatric population.  
 The CRNA should be expected to identify a patient who is at risk for emergence 
agitation. The CRNA is an essential member of a pediatric patients care inside and 
outside of the operating room. The CRNA must know the factors that play a role in 
emergence agitation: age; sevoflurane anesthetic; postoperative pain; separation anxiety; 
patients’ personal character; and type of surgery (Fang et al., 2016). The incidence of 
emergence agitation is highest in pediatric patients who are less than six years old, have 
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preoperative anxiety, and have a rapid emergence from general anesthesia (Stamper et al., 
2014).  
The CRNA must realize the importance of preventing and/or diminishing 
emergence agitation to help with the patient’s overall outcomes. Prevention and quick 
accurate diagnosis are key (Stamper et al., 2014).The use of the standardized tool, the 
PAED, is recommended. A PAED score higher than or equal to 10 determines the 
presence of emergence agitation (Stamper et al.).   The CRNA should ensure proper 
education has been given to PACU nursing staff and various other medical staff who care 
for pediatric postoperative patients, regarding the use of PAED scale and emergence 
agitation itself. 
Certified Registered Nurse Anesthetists are held up to a certain expectation on 
excellent patient care.  Certified Registered Nurse Anesthetists follow policies and 
procedures strictly to ensure proper care is given and can play a leadership role in the 
development of policy and clinical guidelines. They have the expertise and training to  
design and support a policy related to the use of the PAED scale, in order to better ensure  
quick diagnosis and a treatment plan for emergence agitation.  The information from this 
systematic review can be used to improve the care CRNAs provide and how the CRNA 
can educate and support other team members centered in perioperative and postoperative 
care. In order to support nursing education, the CRNA can design, implement, and 
evaluate additional educational tools and programs regarding emergence agitation itself, 
interventions, and diagnosis. Collaboration with the surgeon, anesthesia team, and 
nursing teams regarding emergence agitation is key with an emphasis on continuity of 
care.  
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 The CRNA must know pharmacological interventions for emergence agitation. 
All studies in this systematic review support the use of dexmedetomidine in prevention of 
emergence agitation. Dexmedetomidine is a great choice for pharmacological 
intervention. It is an alpha 2 agonist that provide sedative, analgesic, and anxiolytic 
effects and also lacks respiratory depression. The CRNA can administer 
dexmedetomidine in the perioperative period. Intravenous bolus doses range are 
recommended from 0.5-1mcg/kg, based on how patient tolerates it. If the patient does not 
have an IV, the anesthesia provider can use 1– 2 mcg/kg intranasal dose to prevent 
emergence agitation as well.  
The CRNA must also recognize the mechanism of action of dexmedetomidine 
and the proper treatment of any potential side effects. The CRNA must be mindful of 
each patients’ individual characteristics when administering dexmedetomidine. All 
studies in this systematic review have validated that adverse effects from 
dexmedetomidine are minimal in pediatrics. But the CRNA must be aware of appropriate 
treatment if patient were to become bradycardic or hypotensive; studies have shown that 
atropine should be given if vital signs remain below more than 20% of baseline and 
remain there. Recognition of a patients’ characteristics and swift action related to adverse 
effects based on evidence based knowledge is part of the critical thinking that CRNAs 
must be held too.  
Although all five studies in this systematic review suggest minimal adverse 
effects in pediatrics, no study examined patients with any comorbidities or ASA scores 
greater than two. Studies chose the dose of dexmedetomidine based on previous studies 
and if a regional anesthetic was used. But no study had great rationale for choice of rapid 
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bolus dosing, slow bolus dosing, no bolus, bolus and infusion, and intranasal 
administration of dexmedetomidine. This suggests the need for more research to evaluate 
the most effective administration route for all pediatric patients. The PAED scale was not 
used in all five studies; this suggest the need for more research on the use of the PAED as 
a standardized tool. Research on the use of dexmedetomidine and pediatric emergence 
agitation has the potential to improve patient care, patient quality, patient safety, and 
patient and family satisfaction. Although more research is needed, this systematic review 
can provide information to help prevent, treat, and diagnose the patient with emergence 
agitation.  
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1mcg/kg IV bolus 
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dexmedetomidine 
followed by 0.1 
mcg/kg/h infusion 
 
Group S = saline. 
1 mcg/kg IV 







ASA 1  
Aged 1-5 years  
Hernioplasty 
or orchiopexy 
EA assessed at 
arrival to PACU 
and every 5 
minutes for up to 
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PAED scale used. 
  
 62 
Table A-4     
He, L., Wang, X., Zheng, S., & Shi, Y. (2013). Effects of dexmedetomidine infusion on 
laryngeal mask airway removal and postoperative recovery in children anaesthetized with 
sevoflurane. Anaesthesia and Intensive Care, 41(3), 328–333. doi: 
10.1177/0310057x1304100309 
Purpose Design Sample Surgical 
Procedure 
Method 
To determine the 
effects of two 
different doses of 
dexmedetomidine 






removal and on 
postoperative 
recovery 








Group C = IV 
saline 
 









ASA 1 or 2 
3-7 years old 
Elective 
minor surface 
surgery < than 
an hour long  
No premedication 
Study drug was 
given after LMA 
insertion via 
infusion pump and 
continued for 10 
minutes.  
Lack of scale 
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Dexmedetomidine 
Dose 
Efficacy Adverse Side Effects Limitations 
1 mcg/kg over 10 
minutes followed 
by a 0.1 
mcg/kg/hr 
infusion until end 
of surgery 
EA was lower in group 
D than in group S (5% 
vs 55%). P=0.001 
 
First oral intake and 
discharge time were the 
same in both groups. 
Map and HR decreased 
by 22-28% and 18-21% 
in group D as compared 
to group S.  
Six subjects received 
atropine for bradycardia. 
P=0.020 
Uncertainty of 
proper scoring tool 
for EA due to 
possible subjective 
views. 
Sample size may be 
too small because it 







Data Collection Table: Outcome of the Study  
Di, M., Han, Y., Yang, Z., Liu, H., Ye, X., Lai, H., … Lian, Q. (2017). Tracheal extubation in 
deeply anesthetized pediatric patients after tonsillectomy: a comparison of high-concentration 
sevoflurane alone and low-concentration sevoflurane in combination with dexmedetomidine 
pre-medication. BMC Anesthesiology, 17(1). doi: 10.1186/s12871-017-0317-3 
Dexmedetomidine 
Dose 
Efficacy Adverse Side Effects Limitations 
Group D0 
received IV 
saline. Group D1 
received 
dexmedetomidine 
1 mcg/kg. Group 
D 2 received 
dexmedetomidine 
2 mcg/kg 10 
minutes before 
anesthesia. 
Group D0 6% had EA 
Group D1 0% had EA 
Group D2 0% had EA 
P= 0.05 
Group D0 and D2 had 
longest time to 
discharge Group D0 
33.7% and Group D2 
32.8% 




was not monitored. 
This means the 
correlation between 
length and how 
deep the sedation 




in blood could not 






Data Collection Table: Outcome of the Study  
Chen, F., Wang, C., Lu, Y., Huang, M., & Fu, Z. (2018). Efficacy of different doses of 
dexmedetomidine as a rapid bolus for children: a double-blind, prospective, randomized 
study. BMC Anesthesiology, 18(1). doi: 10.1186/s12871-018-0562-0 
Dexmedetomidine 
Dose 
Efficacy Adverse Side Effects Limitations 


















Group D4 (0.75mcg/kg) 
0% incidence of EA 
Group D 5  
(1 mcg/kg) 0% 




incidence of EA, fewer 
trends noted in D2 and 
D3. 
Group D5 (0%, P < 
0.001)  
Group D4 (0%, P < 
0.001) Group D3 (5%, 
P= 0.096) Group D2 
(5%, P=0.096). 
Group D1 0% 
Group D2 5% 
bradycardia 
Group D3 15% 
bradycardia 
Group D4 10% 
bradycardia 
Group D5 10% 
bradycardia 







Data Collection Table: Outcome of the Study  
He, L., Wang, X., Zheng, S., & Shi, Y. (2013). Effects of dexmedetomidine infusion on 
laryngeal mask airway removal and postoperative recovery in children anaesthetized with 




Efficacy Adverse Side Effects 
Group C received 




Group D 2 




The MAC of 
sevoflurane was lower 
in Group D2 compared 
to Group D1, which 
both were compared to 
Group C.  
Group D1 had lower 
emergence agitation 
(17%, P=0.179), Group 
D 2 (6%, P=0.179), 




prolonged in Group 
D2(8+3 minutes) and in 
Group C (8+3 minutes) 
Recovery time 
prolonged in Group D2 
and Group C (15+6 
minutes). Hemodynamic 
effects seen with higher 
doses 1 mcg/kg, but did 




Surgeries were less 
than one hour.  
General anesthesia 
was combined with 
either local 
anesthesia or an 
anesthetic block.  
Unclear if smaller 
doses of 
dexmedetomidine 
on an infusion 







Table B-5    
Lin, Y., Chen, Y., Huang, J., Chen, H., Shen, W., Guo, W., … Gan, X. (2016). Efficacy of 
premedication with intranasal dexmedetomidine on inhalational induction and postoperative 
emergence agitation in pediatric undergoing cataract surgery with sevoflurane. Journal of 
Clinical Anesthesia, 33, 289–295. doi: 10.1016/j.jclinane.2016.04.027 
Dexmedetomidine 
Dose 
Efficacy Adverse Side Effects Limitations 
Group C received 
saline. Group D1 
received 1 mcg/kg 
and diluted with 
equal volume of 
saline. Group D2 
received 2 mcg/kg 
of 
dexmedetomidine 
and was not 
diluted.  
 
Intranasal dex greatly 
reduced emergence 
agitation.  
Group D1 23.3%, P < 
0.001 
Group D2 10% P < 
0.001 
 Group C 80% 
 
Emergence and PACU 
time all remained the 
same between the 3 
groups. 
 
Intranasal dex improved 
mask induction. 
Reduction in heart rates, 
but did not require 
interventions.  
 
Influence of the 






effects of dex, 
unsure of intranasal 
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extubation in deeply anesthetized pediatric patients after tonsillectomy: a 
comparison of high-concentration sevoflurane alone and low-concentration 
sevoflurane in combination with dexmedetomidine pre-medication. BMC 
Anesthesiology, 17(1). doi: 10.1186/s12871-017-0317-3 
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Cross Study Analysis Tool  
Study 
# 










Group D 5% 











D= 1mcg/kg bolus 







No delays in same day 





6% had EA 
Group D1 
0% had EA 
Group D2 
0% had EA 
P= 0.05 
Seventy-five 
patients. ASA 1 
or 2. Aged 3-7 
years old. 
Tonsillectomy 
Sevoflurane D0= NS 
D1 = 1mcg/kg bolus 
of dex 
D2 = 2mcg/kg bolus 
No interventions 
needed 
Recovery time was 
longest in Group D2. 













(0%, P < 
0.001)  
Group D4 
(0%, P < 
100 patients. 
ASA 1 or 2, 

















D2 = 0.25mcg/kg 
dexmedetomidine IV 
bolus 




D 4 =  
No interventions 
for hypotension. 
Group D1 0% 
Group D2 5% 
bradycardia 
Group D3 15% 
bradycardia 
Group D4 10% 
bradycardia 































ASA 1 or 2. 




Sevoflurane C = saline, D1 = 0.5 
mcg/kg 
dexmedetomidine 
D 2 = 1 mcg/kg 
dexmedetomidine  
Hemodynamic 
effects seen with 
higher doses 1 
mcg/kg, but did 
not exceed 20% 





prolonged in Group 
D2(8+3 minutes) and in 
Group C (8+3 minutes) 
Recovery time prolonged 
in Group D2 and Group 














Ninety ASA 1 






e eye drops 
C = saline. D1 = 1 
mcg/kg 
dexmedetomidine 






heart rates, but 
did not require 
interventions.  
 
Emergence and PACU 
time all remained the 
same between the 3 
groups 
 
 
 
